8-K: TuHURA Biosciences Updates Pro Forma Financials Post-Mergers

TuHURA Biosciences, Inc. filed an 8-K detailing unaudited pro forma financial statements for 2024 and 2025, reflecting its recent acquisitions of Legacy TuHURA and Kineta.

Summary

• TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) has provided unaudited pro forma condensed combined financial statements for the nine months ended September 30, 2025, and the year ended December 31, 2024.
• These pro forma statements integrate the financial results as if the reverse merger with Legacy TuHURA (completed October 18, 2024) and the acquisition of Kineta (completed June 30, 2025) had both occurred on January 1, 2024.
• For the nine months ended September 30, 2025, the pro forma net loss attributable to common stockholders was $(27,808,214), resulting in a net loss per share of $(0.53) based on 59,137,423 weighted-average shares outstanding.
• For the year ended December 31, 2024, the pro forma net loss attributable to common stockholders was $(58,827,514), with a net loss per share of $(1.12) based on 52,737,094 weighted-average shares outstanding.
• The acquisition of Kineta, which includes rights to the novel TBS-2025 antibody, was valued at an estimated total consideration of $16,560,163, comprising cash and shares.
• Key assets acquired from Kineta include $8,261,000 in in-process research and development and $13,554,163 in goodwill.
• TuHURA is progressing with the REM-001 study, aiming to enroll 10 cutaneous metastatic breast cancer patients and complete required follow-up by December 31, 2025, to achieve a Contingent Value Rights (CVR) milestone, which management deems probable.
• The company successfully completed a June 2025 private placement, raising an aggregate offering amount of $12,612,169, with $8,912,151 received to date and the remaining $3,700,018 committed by December 31, 2025.

Sentiment

Score: 6

Explanation: The filing details significant pro forma losses, which is a negative. However, it also outlines strategic mergers, successful capital raises, and ongoing clinical development for multiple assets, indicating forward momentum and potential future value. The 'probable' achievement of a CVR milestone is also a positive. The overall sentiment is cautiously optimistic due to pipeline expansion and funding, despite current losses.

Positives

• Successfully completed two strategic mergers, consolidating operations and expanding the clinical pipeline with the acquisition of Kineta and its TBS-2025 antibody.
• Secured significant funding through a June 2025 private placement, raising $12,612,169 to support ongoing clinical trials and working capital needs.
• Management anticipates the successful achievement of the REM-001 study's CVR milestone by December 31, 2025, which involves enrolling 10 patients and completing follow-up.
• The company plans to continue advancing Kineta's ongoing VISTA-101 clinical trial and explore synergies with its existing studies, indicating a robust development strategy.

Negatives

• Reported significant pro forma net losses of $(27,808,214) for the nine months ended September 30, 2025, and $(58,827,514) for the year ended December 31, 2024.
• No significant value is currently expected from other in-process research and development assets acquired from Kintara, with no plans to restart or advance them.
• The 1.5% royalty on TBS-2025 sales for the July 2024 Private Placement investor is not currently probable or reasonably estimable due to the early clinical stage and inherent regulatory uncertainties.
• Contingent consideration related to Disposed Asset Payment Rights from Kineta is not currently probable or reasonably estimable due to uncertainties surrounding future development, regulatory approval, and third-party agreements.

Risks

• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those set forth in the statements.
• Inherent uncertainties surround the regulatory approval process for clinical assets like TBS-2025, which could impact future commercialization.
• The REM-001 study is in its early stages, with no clinical trials passed or proven efficacy, meaning its potential future value is not yet realized.
• Goodwill of $13,554,163 recognized from the Kineta acquisition is subject to annual impairment testing, which could lead to future accounting charges.
• The final calculation of goodwill and other acquisition accounting estimates may differ materially from the preliminary amounts presented.

Future Outlook

The company plans to continue advancing the clinical development of Kineta's ongoing trials, including the VISTA-101 clinical trial, and explore synergies with its current ongoing studies. Proceeds from the June 2025 Private Placement are earmarked to fund expenses related to the Kineta acquisition, initiate the Phase 3 trial for IFx-2.0, advance TBS-2025 to a Phase 2 trial, and cover other working capital needs. TuHURA also anticipates the successful enrollment of 10 patients in the REM-001 study by December 31, 2025, to achieve a CVR milestone, and will thereafter evaluate the technology's potential future value.

Management Comments

• "TuHURA anticipates the successful enrollment of the ten cutaneous metastatic breast cancer patients and that such patients will complete the required follow-up to complete the trials in accordance with the CVR Agreement (the Milestone)."
• "TuHURAs management has concluded that it is probable that the Milestone will be achieved and shares of TuHURA Common Stock will be issued."
• "Once 10 patients are enrolled and tracked in the REM-001 Study... TuHURA expects to enroll the remaining patients and complete the NIH-funded trial and thereafter evaluate whether the REM-001 technology has potential future value that could be realized by TuHURA."
• "TuHURA does not currently expect to restart or advance any Kintara technologies that were acquired, other than the REM-001 Study."
• "Post-Mergers, TuHURA has announced that the Company will continue advancing the clinical development of Kinetas ongoing trials while also exploring the possibility of certain synergies in combination with TuHURAs current ongoing studies."

Industry Context

This filing illustrates a common strategy in the biotechnology industry where companies engage in mergers and acquisitions to consolidate pipelines, gain access to new technologies (such as the VISTA-inhibiting antibody TBS-2025), and secure necessary funding for costly clinical development. The company's focus on oncology, specifically cutaneous metastatic breast cancer and advanced solid tumors, and its pursuit of targeted therapeutic modalities like PDT photosensitizers and VISTA inhibition, align with current trends in cancer research and treatment. The reliance on private placements and milestone-based funding mechanisms is typical for early to mid-stage biotech companies navigating the capital-intensive drug development process.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The July 2024 Private Placement involved an existing Legacy TuHURA shareholder investing $5,000,000 for shares and a 1.5% royalty on certain TBS-2025 sales.

Stakeholder Impact

• Shareholders: Experience dilution from multiple share issuances related to mergers and private placements, but gain potential for future value from an expanded clinical pipeline (TBS-2025, IFx-2.0, REM-001). They are also exposed to significant ongoing net losses.
• Employees: The former Kintara CEO was not retained post-merger, while TuHURA's senior management and board remained stable, indicating targeted integration.
• Creditors/Suppliers: The Clinical Trial Funding Agreement provided loans to Kineta for R&D expenses, suggesting continued engagement with contract research organizations and vendors.
• Regulatory Bodies: Ongoing interactions with the FDA are implied, particularly regarding the lifting of a partial clinical hold for IFx-2.0, which was a milestone for funding.

Next Steps

• Complete enrollment of 10 cutaneous metastatic breast cancer patients and required follow-up for the REM-001 study by December 31, 2025, to achieve the CVR Milestone.
• Evaluate the potential future value of the REM-001 technology after completing the NIH-funded trial.
• Continue advancing the clinical development of Kineta's ongoing trials, including the VISTA-101 clinical trial.
• Explore potential synergies between Kineta's and TuHURA's current ongoing studies.
• Initiate the Phase 3 trial for IFx-2.0.
• Advance TBS-2025 to a Phase 2 trial.
• Receive the remaining $3,700,018 from the June 2025 Private Placement by December 31, 2025.

Key Dates

Keywords

Biotechnology, Pharmaceuticals, Merger, Acquisition, Clinical Trials, Oncology, Immunotherapy, TBS-2025, REM-001, IFx-2.0, Private Placement, Pro Forma Financials, SEC Filing, Corporate Governance, Risk Factors, Nasdaq